nytimes.com

FDA scrutiny targets microdosing edible products, including chocolate marketed for altered mood or mental effects. The reporting centers on what the FDA can regulate and how unapproved products may be sold as dietary goods or supplements while making drug-like claims. The piece frames the issue as a public health and consumer protection problem, highlighting uncertainty around dosing, efficacy claims, and the safety implications of home and at-home microdosing.